Benjamin F. Edwards & Company Inc. Has $56,000 Holdings in Icon Plc (ICLR)

Share on StockTwits

Benjamin F. Edwards & Company Inc. boosted its stake in Icon Plc (NASDAQ:ICLR) by 36.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 433 shares of the medical research company’s stock after purchasing an additional 116 shares during the quarter. Benjamin F. Edwards & Company Inc.’s holdings in Icon were worth $56,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently modified their holdings of the business. BlackRock Inc. grew its position in Icon by 23.7% in the 2nd quarter. BlackRock Inc. now owns 56,120 shares of the medical research company’s stock worth $7,437,000 after purchasing an additional 10,763 shares during the last quarter. Bank of New York Mellon Corp grew its position in Icon by 10.1% in the 2nd quarter. Bank of New York Mellon Corp now owns 164,947 shares of the medical research company’s stock worth $21,860,000 after purchasing an additional 15,137 shares during the last quarter. Northern Trust Corp lifted its stake in shares of Icon by 3.9% in the 2nd quarter. Northern Trust Corp now owns 304,194 shares of the medical research company’s stock worth $40,315,000 after acquiring an additional 11,287 shares during the period. Bank of Montreal Can lifted its stake in shares of Icon by 1.8% in the 3rd quarter. Bank of Montreal Can now owns 180,581 shares of the medical research company’s stock worth $27,764,000 after acquiring an additional 3,254 shares during the period. Finally, BB&T Corp lifted its stake in shares of Icon by 11.5% in the 3rd quarter. BB&T Corp now owns 4,116 shares of the medical research company’s stock worth $632,000 after acquiring an additional 425 shares during the period. Institutional investors and hedge funds own 88.70% of the company’s stock.

A number of brokerages have recently weighed in on ICLR. UBS Group set a $136.00 price target on shares of Icon and gave the stock a “sell” rating in a research note on Saturday, October 27th. Zacks Investment Research raised shares of Icon from a “sell” rating to a “hold” rating in a research note on Tuesday, January 15th. Mizuho raised shares of Icon from a “neutral” rating to a “buy” rating and upped their price target for the stock from $146.00 to $150.00 in a research note on Friday, January 25th. BidaskClub lowered shares of Icon from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, November 20th. Finally, Goldman Sachs Group lowered shares of Icon from a “conviction-buy” rating to a “buy” rating and set a $168.00 price target for the company. in a research note on Friday, December 14th. Two analysts have rated the stock with a sell rating and nine have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $153.11.

Shares of NASDAQ:ICLR opened at $143.20 on Thursday. The company has a market capitalization of $7.65 billion, a PE ratio of 26.57, a P/E/G ratio of 1.75 and a beta of 0.71. Icon Plc has a twelve month low of $107.25 and a twelve month high of $155.33. The company has a quick ratio of 2.17, a current ratio of 2.17 and a debt-to-equity ratio of 0.26.

ILLEGAL ACTIVITY WARNING: This article was first reported by Macon Daily and is owned by of Macon Daily. If you are accessing this article on another publication, it was illegally copied and republished in violation of international copyright and trademark law. The original version of this article can be accessed at https://macondaily.com/2019/02/14/benjamin-f-edwards-company-inc-has-56000-holdings-in-icon-plc-iclr.html.

Icon Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.

See Also: Understanding Price to Earnings Ratio (PE)

Institutional Ownership by Quarter for Icon (NASDAQ:ICLR)

Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply